GlobeNewswire Inc.··NaSutro Biopharma's ADC Pipeline Shows Promise at AACR 2026 With Multiple Candidates Advancing
Sutro Biopharma presented encouraging preclinical data for its ADC pipeline at AACR 2026, with lead candidate STRO-004 showing robust antitumor activity and plans for IND submissions in 2026.
ALPMYSTROclinical trialsoncology